Illumina (ILMN) to Release Quarterly Earnings on Thursday

Illumina (NASDAQ:ILMN) will likely be issuing its Q4 2025 results after the market closes on Thursday, February 5th. Analysts expect the company to announce earnings of $1.22 per share and revenue of $1.0997 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 5, 2026 at 4:30 PM ET.

Illumina Trading Down 2.5%

ILMN stock opened at $141.13 on Tuesday. Illumina has a 12 month low of $68.70 and a 12 month high of $155.53. The firm’s 50-day moving average is $138.39 and its 200 day moving average is $115.46. The company has a market capitalization of $21.56 billion, a PE ratio of 31.64, a P/E/G ratio of 2.40 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ILMN shares. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Guggenheim increased their price objective on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. JPMorgan Chase & Co. lifted their target price on Illumina from $105.00 to $130.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. Barclays upped their target price on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Illumina currently has an average rating of “Hold” and a consensus price target of $127.18.

Insider Activity at Illumina

In related news, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares in the company, valued at $2,434,241.83. This represents a 1.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.17% of the company’s stock.

Institutional Trading of Illumina

Several hedge funds have recently modified their holdings of ILMN. State Street Corp grew its position in shares of Illumina by 6.8% in the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock worth $569,800,000 after buying an additional 382,520 shares during the last quarter. AQR Capital Management LLC boosted its stake in Illumina by 3.1% in the third quarter. AQR Capital Management LLC now owns 3,398,027 shares of the life sciences company’s stock valued at $315,915,000 after acquiring an additional 102,147 shares in the last quarter. Bank of America Corp DE boosted its stake in Illumina by 1.9% in the second quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after acquiring an additional 35,167 shares in the last quarter. Invesco Ltd. grew its holdings in Illumina by 3.1% in the third quarter. Invesco Ltd. now owns 1,395,255 shares of the life sciences company’s stock worth $132,507,000 after purchasing an additional 42,178 shares during the last quarter. Finally, Legal & General Group Plc increased its position in shares of Illumina by 1.8% during the third quarter. Legal & General Group Plc now owns 1,244,688 shares of the life sciences company’s stock worth $118,208,000 after purchasing an additional 21,565 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.